Goal attainment of cardiovascular disease risk factors and associated patient factors
| . | Blood pressure target . | LLT target, high risk . | LLT target, very high risk . |
|---|---|---|---|
| DAS28CRP | |||
| Remission (<2.6) | 47.9 (960/2003) | 44.0 (350/796) | 17.7 (90/508) |
| Low (2.6–3.2) | 47.7 (284/596) | 46.1 (107/232) | 13.2 (20/151) |
| Moderate (3.3–5.1) | 46.9 (459/978) | 44.8 (151/337) | 16.0 (39/243) |
| High (>5.1) | 51.4 (93/181) | 44.2 (23/52) | 20.5 (9/44) |
| P-value | 0.743 | 0.95 | 0.533 |
| Sex | |||
| Male | 46.7 (831/1781) | 46.6 (287/616) | 20.6 (129/626) |
| Female | 50.5 (2286/4527) | 44.4 (663/1492) | 15.9 (133/834) |
| P-value | 0.007 | 0.392 | 0.026 |
| Age | |||
| <50 | 41.0 (281/685) | 46.2 (67/145) | 17.6 (6/34) |
| 50–60 | 44.5 (631/1418) | 40.0 (146/365) | 15.4 (25/162) |
| 60–70 | 51.2 (1052/2056) | 44.8 (368/821) | 19.1 (79/414) |
| ≥70 | 53.7 (1167/2172) | 47.5 (369/777) | 17.9 (152/850) |
| P-value | <0.001 | 0.126 | 0.786 |
| . | Blood pressure target . | LLT target, high risk . | LLT target, very high risk . |
|---|---|---|---|
| DAS28CRP | |||
| Remission (<2.6) | 47.9 (960/2003) | 44.0 (350/796) | 17.7 (90/508) |
| Low (2.6–3.2) | 47.7 (284/596) | 46.1 (107/232) | 13.2 (20/151) |
| Moderate (3.3–5.1) | 46.9 (459/978) | 44.8 (151/337) | 16.0 (39/243) |
| High (>5.1) | 51.4 (93/181) | 44.2 (23/52) | 20.5 (9/44) |
| P-value | 0.743 | 0.95 | 0.533 |
| Sex | |||
| Male | 46.7 (831/1781) | 46.6 (287/616) | 20.6 (129/626) |
| Female | 50.5 (2286/4527) | 44.4 (663/1492) | 15.9 (133/834) |
| P-value | 0.007 | 0.392 | 0.026 |
| Age | |||
| <50 | 41.0 (281/685) | 46.2 (67/145) | 17.6 (6/34) |
| 50–60 | 44.5 (631/1418) | 40.0 (146/365) | 15.4 (25/162) |
| 60–70 | 51.2 (1052/2056) | 44.8 (368/821) | 19.1 (79/414) |
| ≥70 | 53.7 (1167/2172) | 47.5 (369/777) | 17.9 (152/850) |
| P-value | <0.001 | 0.126 | 0.786 |
DAS28CRP, disease activity score using 28 joints and C-reactive protein; LLT, lipid-lowering treatment.
Goal attainment of cardiovascular disease risk factors and associated patient factors
| . | Blood pressure target . | LLT target, high risk . | LLT target, very high risk . |
|---|---|---|---|
| DAS28CRP | |||
| Remission (<2.6) | 47.9 (960/2003) | 44.0 (350/796) | 17.7 (90/508) |
| Low (2.6–3.2) | 47.7 (284/596) | 46.1 (107/232) | 13.2 (20/151) |
| Moderate (3.3–5.1) | 46.9 (459/978) | 44.8 (151/337) | 16.0 (39/243) |
| High (>5.1) | 51.4 (93/181) | 44.2 (23/52) | 20.5 (9/44) |
| P-value | 0.743 | 0.95 | 0.533 |
| Sex | |||
| Male | 46.7 (831/1781) | 46.6 (287/616) | 20.6 (129/626) |
| Female | 50.5 (2286/4527) | 44.4 (663/1492) | 15.9 (133/834) |
| P-value | 0.007 | 0.392 | 0.026 |
| Age | |||
| <50 | 41.0 (281/685) | 46.2 (67/145) | 17.6 (6/34) |
| 50–60 | 44.5 (631/1418) | 40.0 (146/365) | 15.4 (25/162) |
| 60–70 | 51.2 (1052/2056) | 44.8 (368/821) | 19.1 (79/414) |
| ≥70 | 53.7 (1167/2172) | 47.5 (369/777) | 17.9 (152/850) |
| P-value | <0.001 | 0.126 | 0.786 |
| . | Blood pressure target . | LLT target, high risk . | LLT target, very high risk . |
|---|---|---|---|
| DAS28CRP | |||
| Remission (<2.6) | 47.9 (960/2003) | 44.0 (350/796) | 17.7 (90/508) |
| Low (2.6–3.2) | 47.7 (284/596) | 46.1 (107/232) | 13.2 (20/151) |
| Moderate (3.3–5.1) | 46.9 (459/978) | 44.8 (151/337) | 16.0 (39/243) |
| High (>5.1) | 51.4 (93/181) | 44.2 (23/52) | 20.5 (9/44) |
| P-value | 0.743 | 0.95 | 0.533 |
| Sex | |||
| Male | 46.7 (831/1781) | 46.6 (287/616) | 20.6 (129/626) |
| Female | 50.5 (2286/4527) | 44.4 (663/1492) | 15.9 (133/834) |
| P-value | 0.007 | 0.392 | 0.026 |
| Age | |||
| <50 | 41.0 (281/685) | 46.2 (67/145) | 17.6 (6/34) |
| 50–60 | 44.5 (631/1418) | 40.0 (146/365) | 15.4 (25/162) |
| 60–70 | 51.2 (1052/2056) | 44.8 (368/821) | 19.1 (79/414) |
| ≥70 | 53.7 (1167/2172) | 47.5 (369/777) | 17.9 (152/850) |
| P-value | <0.001 | 0.126 | 0.786 |
DAS28CRP, disease activity score using 28 joints and C-reactive protein; LLT, lipid-lowering treatment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
